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Nicotine addiction is a global health problem that affects 
nearly one-third of the population. Animal models have 
shown that the beta-4 subunit of nicotinic acetylcholine 
receptors (nAChR) expressed in the habenulo-
interpeduncular pathway plays a particularly important 
role in modulating many of the symptoms of nicotine 
withdrawal in mice. Ibogaine, a naturally occurring 
compound extracted from the root bark of a West African 
shrub, has been shown to reduce drug self administration 
in animal models of addiction. Ibogaine is considered to 
be a dirty drug due to its nonspecific interaction at a 
variety of receptor subtypes. This “nonspecificity” 
contributes to its hallucinogenic, tremorigenic, and 
cardiovascular compromising properties. It is thought that 
the anti-addictive effects of ibogaine are due to its 
antagonism of the α3β4 nAChR. In this study we explore 
the interaction of ibogaine on the α3β4 nAChR with the 
hope of developing more selective, more effective 
therapeutics in the treatment of addiction. 
This research was supported by the IdEA Network of Biomedical Research Excellence 
(INBRE) through an undergraduate student project support (USPS) fellowship. Thanks to 
Dr. Marvin Schulte for his wisdom and guidance as I continue to work on this project.   
Xenopus Laevis oocytes were injected with mRNA coding 
for the human α3β4 nicotinic acetylcholine receptor, and 
incubated for 24-36 hours. Electrophysiological 
recordings were done using a technique known as two 
electrode voltage clamp. Compounds were classified 
according to their IC/EC50 values, the concentrations 
required to inhibit a response by 50%, or elicit a 50% of 
maximum response. 
 
Definitions: 
Agonist: A compound that elicits a physiological response 
when it binds to its specific receptor. 
 
Antagonist: A compound that interferes with the 
physiological action of an agonist.   
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Acknowledgements 
•  Ibogaine and 18-MC inhibit 100% of agonist induced 
ion flux. 
•  Ibogaine has an IC50 of 2.0±1.1 µM 
•  18-MC has an IC50 of 5.8±1.1 µM 
•  High affinity at the α3β4 nAChR suggests a particularly 
important role for this receptor in addiction. 
Fig 1. ACh dose response curve. The endogenous agonist 
acetylcholine was determined to have an EC50 of 182±1.5  
µM at the hα3β4 nAChR. Each point represents N=4 
replicates. 
Fig 2. Nicotine dose response curve. The partial 
agonist nicotine was determined to have an EC50 of 
56.2±1.2 µM at the hα3β4 nAChR. Each point represents 
N=4 replicates. 
Fig 3. Ibogaine inhibition curve. Increasing ibogaine 
concentrations inhibit 100% of 100 µM ACh induced ion 
flux. Ibogaine was determined to have an IC50 of 2.0±1.1 
µM at the hα3β4 nAChR. Each point represents N=4 
replicates. 
Fig 4. 18-MC inhibition curve. Increasing 18-MC 
concentrations inhibit 100% of 100 µM ACh induced 
ion flux. 18-MC was determined to have an IC50 of 
5.8±1.1 µM at the hα3β4 nAChR. Each point represents 
N=4 replicates. 
Fig 5. ACh dose response in 10 µM 18-MC. The ability 
of ACh to overcome inhibition by 18-MC suggest the 
possibility of a competitive mode of inhibition. In the 
presence of 10 µM 18-MC ACh EC50 value is ~ 3.45 times 
larger (625±1.2 µM) than in the absence. Each point 
represents N=4 replicates. 
ACh 
Ligand 
Acetylcholine 
EC50 µM 
181.7 
Nicotine 56.2 
Ibogaine IC50 µM 
 
2.0 
18-MC 5.8 
Table 1. Summary of Results 
EC/IC50 values obtained are in accordance with those 
found in the literature. Ibogaine and its derivative 18-MC 
were both found to inhibit 100% of acetylcholine induced 
ion flux through the hα3β4 nAChR. Evidence suggest that 
antagonism of the hα3β4 receptor plays a particularly 
important role in mediating withdrawal symptoms in the 
habenulo-interpeduncular pathway. 18-MC retains the 
same high affinity for this receptor subtype that is required 
to be an effective therapeutic.  
 
It is currently thought that ibogaine inhibits the hα3β4 
nAChR in a noncompetitive manner. Preliminary evidence 
shows that increasing ACh concentrations is able to 
overcome 18-MC inhibition (Fig 5), suggesting a 
competitive mode of inhibition. This data is not 
conclusive however, further experiments must be 
conducted to determine the voltage dependence of 
ibogaine binding.  
 
Future Work: 
•  Determine Ibogaine/18-MC binding site 
•  Explore the voltage dependence of Ibogaine and 18-MC 
so as to determine channel block.       
